Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions
Nephrolithiasis, Uric Acid
Interventions
DRUG

Pioglitazone 45 mg

45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study

BEHAVIORAL

Weight Loss

Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.

OTHER

Pioglitazone + Weight Loss

Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.

Trial Locations (1)

75390-9107

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT04370093 - Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss | Biotech Hunter | Biotech Hunter